Fisher Sarah C, Van Zutphen Alissa R, Romitti Paul A, Browne Marilyn L
Congenital Malformations Registry, New York State Department of Health, Albany, NY, USA.
Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, Rensselaer, NY, USA.
Matern Child Health J. 2018 Feb;22(2):237-246. doi: 10.1007/s10995-017-2395-8.
Background Small for gestational age (SGA) birth is associated with poor long-term health outcomes. It is unclear whether maternal antihypertensive medication increases risk of SGA independently of maternal hypertension. Methods We analyzed associations between maternal hypertension and antihypertensive medication use and SGA among non-malformed singleton controls in the National Birth Defects Prevention Study. We defined SGA as birthweight < 10th percentile for a given gestational age, sex, race/ethnicity, and parity. We included 1045 SGA and 10,019 non-SGA births. We used logistic regression to calculate adjusted odds ratios (AORs) and 95% confidence intervals (CIs). We assessed interaction between hypertension, antihypertensive use, and maternal race/ethnicity and age. Results Overall, 122 (11.7%) SGA and 892 (8.9%) non-SGA mothers reported hypertension and 21 (2.0%) SGA and 154 (1.5%) non-SGA mothers reported antihypertensive use. The most commonly reported medications were centrally-acting antiadrenergics, β-blockers, calcium channel blockers, and diuretics. Compared to normotensive pregnancies, maternal hypertension, regardless of treatment (AOR, 1.49 [95% CI, 1.20, 1.86]), and untreated maternal hypertension [AOR, 1.46 (95% CI, 1.15, 1.86)] were associated with SGA. We observed a positive, but not significant, association between antihypertensive use and SGA. SGA risk varied by maternal race/ethnicity, being highest among Hispanic mothers, and age, being highest among mothers ≥ 35 years, but statistical tests for interaction were not significant. Conclusions Consistent with the literature, our findings suggest that maternal hypertension slightly increases SGA risk. We did not observe an appreciably increased SGA risk associated with antihypertensive medication use beyond that of the underlying maternal hypertension.
小于胎龄儿(SGA)出生与不良的长期健康结局相关。尚不清楚母亲使用抗高血压药物是否会独立于母亲高血压而增加SGA风险。方法:我们在国家出生缺陷预防研究中分析了非畸形单胎对照中母亲高血压、抗高血压药物使用与SGA之间的关联。我们将SGA定义为给定胎龄、性别、种族/族裔和产次下出生体重低于第10百分位数。我们纳入了1045例SGA出生和10019例非SGA出生。我们使用逻辑回归计算调整后的优势比(AOR)和95%置信区间(CI)。我们评估了高血压、抗高血压药物使用与母亲种族/族裔和年龄之间的相互作用。结果:总体而言,122例(11.7%)SGA母亲和892例(8.9%)非SGA母亲报告患有高血压,21例(2.0%)SGA母亲和154例(1.5%)非SGA母亲报告使用抗高血压药物。最常报告的药物是中枢作用抗肾上腺素能药物、β受体阻滞剂、钙通道阻滞剂和利尿剂。与血压正常的妊娠相比,母亲高血压,无论是否治疗(AOR,1.49 [95% CI,1.20,1.86]),以及未经治疗的母亲高血压[AOR,1.46(95% CI,1.15,1.86)]均与SGA相关。我们观察到抗高血压药物使用与SGA之间存在正相关,但不显著。SGA风险因母亲种族/族裔而异,在西班牙裔母亲中最高,因年龄而异,在≥35岁的母亲中最高,但相互作用的统计检验不显著。结论:与文献一致,我们的研究结果表明母亲高血压会轻微增加SGA风险。我们未观察到与抗高血压药物使用相关的SGA风险有明显增加,超出了潜在的母亲高血压风险。